Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CHKA | P35790 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | DNM2 | P50570 | 2/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21503637 | 0.98 | CA2 (0.43) | CA2CHKAKCNH2GABRA2GABRB2 | |
| SCHEMBL24973136 | 0.86 | CA2 (0.47) | CA2CHKAGABRA2GABRB2MAPT | |
| SCHEMBL1685607 | 0.82 | KCNH2 (0.52) | KCNH2PTGS2ALDH1A1MAPTPPARA | |
| SCHEMBL2495475 | 0.80 | KCNH2 (0.48) | KCNH2GABRA2GABRB2PTGS2ALDH1A1 | |
| SCHEMBL24798597 | 0.75 | KCNH2 (0.46) | KCNH2PTGS2ALDH1A1MAPTPPARA | |
| SCHEMBL21503708 | 0.75 | KCNH2 (0.42) | KCNH2GABRA2GABRB2FAAHALDH1A1 | |
| SCHEMBL19619562 | 0.75 | KCNH2 (0.42) | KCNH2GABRA2GABRB2FAAHALDH1A1 | |
| SCHEMBL17495322 | 0.72 | KCNH2 (0.39) | KCNH2GABRA2GABRB2FAAHALDH1A1 | |
| SCHEMBL21503698 | 0.72 | GABRA2 (0.45) | KCNH2GABRA2GABRB2ALDH1A1 | |
| SCHEMBL22166092 | 0.72 | LOXL2 (0.56) | PTGS2FAAHALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-05 | — | — | US | disclosed |
| US-11572364-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572364-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | CA2 4030/4885CHKA 1613/4885KCNH2 4273/4885 |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | CA2 4030/4885CHKA 1613/4885KCNH2 4273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.